When, Why, and How to Initiate and Intensify Insulin in Type 2 Diabetes

Wednesday, October 20, 2021
1200 – 1300 h EDT | 0900 – 1000 h PDT

Join us for the third webinar in the Diabetes Management series. With insulin initiation being a major area for clinical inertia, this webinar will focus on challenges and barriers to insulin initiation and provide guidance on when insulin should be considered and the regimens to use for patients. This will review key considerations for these patients from a holistic approach to diabetes management.

FACULTY:

• Dr. David Strain, MBChB, MD, FRCP (Moderator)
• Dr. Roopa Mehta, MBBS, MRCP
• Dipesh Patel, BSc, MBBS PhD, MRCP
• Rene Wong, MD, FRCPC, MEd

For MORE INFORMATION and REGISTRATION, click here.

LEARNING OBJECTIVES:

• Review the role of insulin in the management of type 2 diabetes
• Determine which patients are candidate for the use of basal insulin
• Mitigate patient and clinician barriers to using insulin in type 2 diabetes
• Prescribe and intensify an insulin regimen for patients with type 2 diabetes

This program has been supported by an independent educational grant provided by Novo Nordisk A/S.

The Diabetes Management series has been developed in collaboration with the following partners:

3^rd Canadian Acromegaly Summit

To register, click here.

With the continued uncertainty related to the COVID-19 pandemic, Diabetes Canada, CSEM, and the National Planning Committee have collectively decided to offer the 2021 Professional Conference as a virtual experience from November 23–26, 2021.

Registration is now open, click here!

Abstract submission is now open!

• Abstracts for the CSEM general endocrinology and metabolism program are now being accepted for the 2021 Diabetes Canada/CSEM Professional Conference. Submissions are accepted from researchers, endocrinologists and trainees. Submit within the next week to take advantage of the early bird rate for $25.00 per abstract until Wednesday, May 19, 2021, 5:00 PM EDT. After May 19, the regular fee will be $45.00. Abstract submission closes on Wednesday, June 2, 2021, 11:59 PM EDT. Click here to submit a general abstract.
• CSEM is now accepting abstracts for resident clinical vignettes or proposed/in-progress basic science or translational research projects. Oral presentations and e-posters will be pre-recorded and presented virtually during the 2021 Diabetes Canada/CSEM Professional Conference. Submission deadline: Monday, September 6, 2021 at 11:59 PM EDT. Click here to submit a resident clinical vignette or proposed research project abstract.

The conference website will be updated as more information becomes available.

CSEM has received questions from its members regarding the eligibility and safety of the COVID-19 vaccines and patients with endocrine conditions. Health Canada recommendations are changing rapidly. Recognizing there is little data to address groups excluded in the vaccine trials, a risk benefit assessment will need to be case-by-case and in consideration of national, provincial and local regulations.

CSEM supports equitable access to COVID-19 vaccines for individuals with endocrine conditions. Patients with type 1 diabetes, other autoimmune conditions, and immunocompromised health should have a risk/benefit discussion with their health care provider to make an informed decision. Some patients have multiple comorbidities that affect their vaccine status and patients may need to discuss with the relevant specialist(s).

Please see our statement for resources and references, including Diabetes Canada's statement.

View the CSEM 2020 Annual Report here.